---
title: "iX Biopharma Ltd. (42C.SG) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/42C.SG/overview.md"
symbol: "42C.SG"
name: "iX Biopharma Ltd."
parent: "https://longbridge.com/en/quote/42C.SG.md"
datetime: "2026-04-16T07:36:16.217Z"
locales:
  - [en](https://longbridge.com/en/quote/42C.SG/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/42C.SG/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/42C.SG/overview.md)
---

# iX Biopharma Ltd. (42C.SG) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | SG Market |
| Address | No. 14-01 Great World City East Lobby, 1 Kim Seng Promenade, Singapore, Singapore |
| Website | [www.ixbiopharma.com](https://www.ixbiopharma.com) |

## Company Profile

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, and insomnia. The company is also developing Wafermine, a racemic ketamine sublingual wafer, which has completed phase-2 clinical trial for the treatment of complex regional pain syndrome, as well as psychiatric conditions, including depression; iXB 401, a sublingual semaglutide wafer that is in pre-clinical development for the treatment of Type 2 Diabetes and Obesity; SL-NAD+, a sublingual NAD+ wafer to increase the body’s NAD+ levels, energy levels, and alertness; iXB 120 that has completed Phase I clinical trial for acute agitation; IXB-214, which has completed Phase I clinical trial for complex regional pain syndrome; and IXB-314 that has completed Phase I clinical trial for treatment resistant depression.

## Key Executives

| Name | Title |
|------|-------|
| Yip Hang Lee | Executive Chairman & CEO |
| Sien Lup Chew | Chief Financial Officer |
| Janakan Krishnarajah | COO & Chief Medical Officer |
| Iain Bruce Cook | Chief Scientist |
| Chin Beng Lim | Chief Pharmacist |
| Patrick Donald Davies | Non-Executive Lead Independent Director |
| Woon Keng Teo | Independent Non-Executive Director |
| Shing Tung Ho | Non-Executive Non-Independent Director |
| Yandi Liu | Member of Scientific Advisory Board |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| Yip Hang Lee | 22.87% | 2026-02-23 |
| CGS International Securities Singapore Pte. Ltd. | 11.33% | 2025-09-26 |
| Phuah Bee Lee | 5.99% | 2025-10-31 |
| Boon Lock Seah | 3.32% | 2025-09-26 |
| C2c Biopharma Holdings Pte. Ltd | 1.60% | 2025-09-26 |
| Hwee Hoon Chan | 1.47% | 2025-09-26 |
| Wetwaters 8 (S) Pte Ltd | 1.46% | 2025-09-26 |
| Shing Tung Ho | 1.15% | 2025-09-26 |
| Beng Hock Sng | 1.08% | 2025-09-26 |
| Hardeep Kaur | 1.05% | 2025-09-26 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Specialty Pharmaceuticals | 7070000 | 86.41% |
| Nutraceutical | 1112000 | 13.59% |
| Inter-Segment Sales | -415000 | % |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "iX Biopharma Ltd. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Specialty Pharmaceuticals",
        "ratio": 86.41
      },
      {
        "segment": "Nutraceutical",
        "ratio": 13.59
      },
      {
        "segment": "Inter-Segment Sales",
        "ratio": null
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## Geographic Segments

| Region | Revenue | Ratio |
|--------|---------|-------|
| Australia | 6662000 | 85.77% |
| China | 647000 | 8.33% |
| Singapore and Others | 318000 | 4.09% |
| United States of America | 140000 | 1.8% |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**